Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > FDA’s comment

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Dec 17, 2022 2:51pm

290 Views

Post# 35177806

RE:RE:FDA’s comment

Good point SF....& this viral-vector gene therapy not only has more precautions/warnings, the need to use a viral vector in its production & the complex processes involved in its manufacturing will certainly drive up the final price tag. My guess is the "health-benefit" price of Adstiladrin will end up being significantly higher than that of TLD-1433...all imo. Good luck...

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide